

LadHyX Seminar – September 17, 14:00

Raphael Tomasi
(LadHyX / Okomera)

Okomera: accelerating cancer therapy

Okomera is a newly incorporated spin-off from LadHyX, whose key mission is to accelerate the development of modern cancer therapies with microfluidic 3D cellular assays. Our first clients are using our technology to develop better models for clinical decision making in cancer precision medicine. We believe our technology has the power to predict patient-specific responses to therapy. Our technology automates biologically relevant biopsy testing with 3D live-cell assays : cells are first cultivated inside thousands of microfluidic droplets, and then exposed to hundreds of separate conditions in parallel. This technology is based on work initiated at LadHyX in 2013 by cofounders Raphaël TOMASI and Charles BAROUD. First, we will present the company's mission, then we will discuss how we use this droplet microfluidic technology to build relevant and multiplexed 3D cell culture models. Eventually, we will detail one application, recently published in Cell Reports, that led to the discovery of a tissue-level dynamic response to drug exposure.